What Happens When You Stop Tirzepatide?
Reviewed by the MaxLife operations team. Pricing is accurate as of November 2026 and subject to change.
Key Takeaways
- In SURMOUNT-4, 89.5% of people who stayed on Zepbound kept at least 80% of their weight loss at week 88, compared with 16.6% of those switched to placebo.
- The Zepbound label's maintenance doses are 5, 10 and 15 mg. In SURMOUNT-MAINTAIN (2026), dropping from 10 or 15 mg to 5 mg kept all but about 5.6 kg (12 lb) of the loss after a year.
- The Zepbound label has no tapering schedule and no restart dose after a long break, so your prescriber decides how you stop and how you start again.

When you stop tirzepatide, most people regain a large part of the weight they lost, and the blood pressure and blood sugar gains that came with it fade too. In the SURMOUNT-4 trial of Zepbound® (brand tirzepatide), adults who had lost an average of 20.9% of their body weight in 36 weeks and were then switched to a placebo regained 14.0% of their weight over the next year, while those who kept taking it lost another 5.5%. A 2026 trial found that stepping down to a lower dose kept most of the loss. Facts checked November 2026; your prescriber decides whether and how you stop.
What Happens to Your Weight When You Stop Tirzepatide?
Weight usually comes back steadily once you stop, fastest in the first months. In SURMOUNT-4, 783 adults without diabetes took Zepbound for 36 weeks, stepping up to 10 or 15 mg. The 670 who completed that period were then randomly assigned to keep taking it or to switch to a placebo for 52 weeks, without knowing which they got. The placebo group's weight rose 10.0% by week 64, 28 weeks after the switch, and 14.0% by week 88.
- Most kept the loss only if they stayed on it. At week 88, 89.5% of people still on Zepbound had kept at least 80% of their weight loss, compared with 16.6% of the placebo group.
- Stopping didn't erase everything. The placebo group still ended 9.9% below their starting weight on average, and 70.3% of them were at least 5% lighter than when they began.
- Diet and exercise advice alone didn't prevent it. Everyone in the trial, on Zepbound or placebo, had counseling on a reduced-calorie diet and at least 150 minutes of activity a week.
Regain isn't the same for everyone. A 2026 analysis of the trial looked at 308 people who had lost at least 10% before switching to placebo. A year later, 54 had regained less than a quarter of what they lost, 77 a quarter to half, 103 half to three quarters, and 74 three quarters or more. So about 1 in 6 kept most of their loss without the medicine, and about 1 in 4 regained three quarters or more.
Outside trials, the picture is more mixed. In a 2026 study of 7,938 patients at a large health system in Ohio and Florida who stopped semaglutide or tirzepatide after 3 to 12 months, average weight barely changed in the following year (up 0.5% for people treated for obesity), but individual results varied widely. These patients had lost less before stopping (8.4% on average), and many didn't stay off: 1 in 5 restarted the same medicine within a year, and about a third started another obesity treatment.
Why does the weight come back?
The Zepbound label says tirzepatide "decreases calorie intake" and that the effect is "likely mediated by affecting appetite." Its half-life is about 5 to 6 days, so most of it has left your body about a month after the last shot (our guide to how long tirzepatide stays in your system has the week-by-week table). Your body also pushes back after weight loss: in a 2011 NEJM study, hunger hormones and hunger itself were still raised a year after people lost weight on a diet. SURMOUNT-4 didn't publish appetite scores after the switch, but the steady regain in the placebo group fits appetite coming back.
What Else Comes Back: Blood Pressure, Blood Sugar and Waist Size
The health gains that came with the weight loss faded as the weight returned. The Zepbound label reports these SURMOUNT-4 averages:
SURMOUNT-4 · Zepbound label
What came back after people stopped Zepbound
Everyone took Zepbound for 36 weeks, stepping up to 10 or 15 mg. Then half switched to a placebo for 52 weeks without knowing it.
| Measure | Weeks 0 to 36, on Zepbound | Next 52 weeks, switched to placebo | Next 52 weeks, stayed on Zepbound |
|---|---|---|---|
| Body weight | −20.9% | +14.0% | −5.5% |
| Waist | −17.8 cm | +7.8 cm | −4.3 cm |
| Systolic blood pressure | −11.2 mmHg | +8.2 mmHg | +2.0 mmHg |
| Diastolic blood pressure | −5.1 mmHg | +3.2 mmHg | −0.7 mmHg |
| HbA1c (blood sugar) | −0.5 points | +0.3 points | 0.0 points |
| Heart rate | +5.0 beats/min | −5.2 beats/min | −2.1 beats/min |
Averages from the Zepbound prescribing information (revised August 2026), Study 4 (SURMOUNT-4), Tables 6 and 7. Weight changes are percent of the weight at the start of each period; HbA1c started at 5.5%. 670 adults without diabetes; Lilly-funded trial of brand Zepbound. These results have not been shown for compounded tirzepatide.
In plain terms, systolic blood pressure gave back most of its 11.2 mmHg drop, waist size regained about 3 of the 7 inches lost, and HbA1c, a 3-month average of blood sugar, rose 0.3 points in people who didn't have diabetes. Heart rate, which rises a little on tirzepatide, went back down.
How much came back tracked how much weight came back. In the 2026 analysis, people who regained less than a quarter of their loss kept their waist, cholesterol and insulin improvements, although their systolic pressure still rose 6.8 mmHg. Those who regained three quarters or more saw their waist grow 14.7 cm and their systolic pressure rise 10.4 mmHg.
For long-term blood sugar, the 3-year SURMOUNT-1 results in adults with obesity and prediabetes are the clearest: 1.3% of those on tirzepatide developed type 2 diabetes in 176 weeks, compared with 13.3% on placebo. After 17 weeks off treatment, 2.4% of the former tirzepatide group had diabetes, still far below the placebo group's 13.7%.
If you take tirzepatide as Mounjaro® for type 2 diabetes, your blood sugar is likely to rise after stopping. A 2025 review of 18 trials found HbA1c rose 0.65 points on average after people with type 2 diabetes stopped a GLP-1 medicine. Your prescriber may need to adjust your other diabetes medicines.
Are There Withdrawal Symptoms When You Stop?
The Zepbound label doesn't describe withdrawal symptoms or give a tapering schedule, and in SURMOUNT-4 people went straight from 10 or 15 mg to placebo. Stomach side effects became less common after the switch: in the following year, nausea was reported by 2.7% of the placebo group, compared with 8.1% of those who stayed on Zepbound. The changes the trial measured after stopping were in weight and in the heart and blood sugar numbers above. Side effects caused by the drug would be expected to ease as it clears over the following weeks; call your provider if anything is severe or doesn't improve.
What Is a Tirzepatide Maintenance Dose?
On the Zepbound label, a maintenance dose is the weekly dose you stay on after the step-up: 5 mg, 10 mg or 15 mg, listed for "weight reduction and long-term maintenance." The 2.5 mg starting dose "is for treatment initiation and is not approved as a maintenance dosage." Your prescriber picks the maintenance dose based on how you respond and what you tolerate, and the label lets them "consider a lower maintenance dosage" if a higher one is hard to tolerate. The full step-up schedule is in our tirzepatide dosage chart.
So in the label's sense, a maintenance dose isn't a special lower dose for after you reach your goal. When people search for a "maintenance dose after weight loss," they usually mean something else: can I drop to a lower dose and keep the weight off? One randomized trial has tested exactly that.
SURMOUNT-MAINTAIN · 2026
Lower dose, full dose or stopping
Average change from starting weight after 60 weeks on Zepbound at 10 or 15 mg, then one year on the option shown.
SURMOUNT-MAINTAIN, The Lancet 2026: 441 adults took Zepbound at 10 or 15 mg for 60 weeks; 378 were then randomly assigned to the three groups for 52 weeks. Bars: change from starting weight at week 112. People who regained half or more of their loss could get rescue tirzepatide from week 84. Weights in kg: Lilly, May 12, 2026 (placebo not reported in kg). Lilly-funded trial of brand Zepbound; not shown for compounded tirzepatide.
In SURMOUNT-MAINTAIN (The Lancet, 2026), 441 adults took Zepbound at 10 or 15 mg for 60 weeks. Then 378 were randomly assigned to stay on that dose, drop to 5 mg, or switch to placebo for another year:
- Stayed on 10 or 15 mg: kept all of their loss on average, going from 89.5 kg (197 lb) at week 60 to 88.7 kg a year later, according to Lilly.
- Dropped to 5 mg: kept most of it, regaining about 5.6 kg (12 lb) on average, from 89.0 kg to 94.6 kg.
- Results varied: 25% of the 5 mg group regained at least half of their loss and needed rescue treatment, compared with 8% of the full-dose group and 67% of the placebo group.
A lower dose kept more weight off than stopping, but less than staying on the full dose. Other approaches you may read about, such as spacing doses out to every other week or tapering slowly to nothing, haven't been tested in a randomized trial: the main evidence is a 2026 case series of 30 patients, mostly on every-other-week doses. Those are off-label choices for your prescriber, not a plan to try on your own. Our post on tirzepatide microdosing covers doses below the label's.
Should You Stop, Taper or Lower Your Dose?
Whether to stop, taper or lower your dose is a decision for you and your prescriber. Here is what the trials show for each option:
| Option | What the evidence shows |
|---|---|
| Stay on 10 or 15 mg | Kept all of the loss for another year on average, or lost more |
| Lower to 5 mg | Kept most of it; average regain about 5.6 kg (12 lb) in a year |
| Stop all at once | Weight up 14.0% in a year on average; about 1 in 6 kept most of the loss |
| Taper or space doses out | Not tested in a randomized trial |
Questions worth taking to your prescriber:
- Why do I want to stop? Side effects, cost, reaching a goal and planning a pregnancy each point to different options, such as a lower dose for side effects.
- What will we watch after a change? Weight, waist, blood pressure and, if you have diabetes or prediabetes, blood sugar.
- When would we change course? Agree on a weight gain that would prompt a check-in, and what you'd do then.
- Do my other medicines need adjusting? Blood pressure and diabetes medicines may need a new dose as your weight changes.
Sometimes stopping isn't optional. The Zepbound label says to stop if pancreatitis is suspected (severe stomach pain that may spread to the back), if a serious allergic reaction happens, and when a pregnancy is recognized. Get medical care right away for the first two and call your prescriber for the third.
Is It the Same When You Stop Semaglutide or Other GLP-1s?
Yes, the pattern is the same when people stop semaglutide and other GLP-1 medicines. In STEP 4, adults who switched from Wegovy® to placebo after 20 weeks regained 6.9% of their weight over the next 48 weeks, while those who stayed on it lost another 7.9%. In the STEP 1 extension, people who stopped Wegovy after 68 weeks regained about two thirds of their loss within a year, and most of their heart and blood sugar gains faded.
Across 37 studies of weight-loss medicines, a 2026 BMJ review found weight came back at about 0.4 kg (about 1 lb) a month after stopping, faster than after diet and exercise programs, and projected that heart and blood sugar markers return to where they started within about 1.4 years. Switching to a daily pill is another route that has been tested: see Foundayo vs Zepbound.
Restarting Tirzepatide After a Break
How you restart depends on how long you've been off. For a single missed weekly dose, the label rule is simple: take it within 4 days (96 hours), or skip it and keep your usual day. Our guide to the best time to take tirzepatide covers missed doses and changing your injection day.
For a longer break, the label gives no restart dose, so your prescriber decides. Your provider may restart you at a lower dose: the label says most nausea, vomiting and diarrhea in the trials happened while the dose was being raised. Tell your provider the date of your last injection and the dose you were on.
If you pay cash for Zepbound through LillyDirect, a break can also change the price. As of November 2026, the 7.5 mg to 15 mg doses start at $449 a month when you refill within 45 days, and cost $499 (7.5 mg) or $699 (10 mg and up) if you don't. The 5 mg dose starts at $399.
What Helps You Keep Weight Off After Tirzepatide?
Habits help, but in the trials they rarely replaced the medicine on their own: everyone in SURMOUNT-4 had diet and activity counseling, and most of the placebo group still regained. They still matter: the NIH says healthy eating and more activity "may help you regain less weight or keep it off." The best-supported habits:
- Move more than the minimum. The NIH's weight-management guidance starts at 150 minutes of moderate activity and 2 days of muscle strengthening a week, and says you "may need to do more than 300 minutes of moderate-intensity activity a week to reach or maintain your weight-loss goal." Our exercise guide for GLP-1 users shows how to build up to it.
- Keep your muscle. A 2025 joint advisory from four medical and nutrition societies recommends resistance training and enough protein to protect muscle and bone during GLP-1 treatment; see how much protein you need. The same advisory notes that the best diet for keeping weight off after stopping still needs more study.
- Weigh yourself often and act early. In the STOP Regain trial, adults who had lost about 19 kg (42 lb) and learned a daily-weighing routine in face-to-face sessions were less likely to regain 2.3 kg (5 lb) or more over 18 months: 45.7%, compared with 72.4% of those who got newsletters only.
- Keep a plan with your provider. Decide in advance what weight change would bring you back for a check-in, and whether a lower dose, a restart or another medicine would be next.
What MaxLife Members Ask About Stopping or Pausing
Two questions come up again and again from MaxLife members on this topic. The first is which dose to take at the next refill: move up, stay or step down. The second is whether they can pause or skip a refill, usually because they still have medication on hand or have travel or a busy stretch coming up. Some members write that they've reached their goal and want to know what maintenance looks like.
All of these start with your provider. Before each refill, a short check-in asks for your weight, current dose, appetite, side effects and the date of your last injection, and your provider approves each refill and dose. That check-in is the place to say you'd like to stay where you are, step down or stop, and why. If it has been more than 2 weeks since your last injection, contact your care team before your next dose, because your provider may want to change the dose you restart on.
Through MaxLife, compounded tirzepatide is $120 a month, flat: all-inclusive, the same price at every dose, with no membership fee, so stepping down to a lower dose doesn't change what you pay. You can cancel anytime with notice before your next billing period. If cost is the reason you're thinking of stopping a GLP-1 elsewhere, the intake asks for proof of your current prescription and the date of your last injection, so the provider can take your current dose into account; our guide to switching to tirzepatide explains how that works. An independent licensed provider decides whether treatment is right for you, and a licensed partner pharmacy prepares and ships it. MaxLife is a patient management platform, not a pharmacy. Compounded tirzepatide is not FDA-approved, and the trial results on this page belong to Zepbound; they have not been shown for compounded tirzepatide.
How we made this page: we researched it from the sources listed below and drafted it with the help of AI tools. The MaxLife operations team reviews every page before it goes live, and a licensed clinician also reviews our medical articles.
Frequently Asked Questions
Compounded Tirzepatide: $120/mo Flat, All-Inclusive
MaxLife compounded tirzepatide: $120 a month, flat. All-inclusive, no membership fee, the same price at every dose. A licensed provider decides.
Check Your EligibilityThis article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Individual results vary. Pricing, insurance coverage, and compounding regulations described here are subject to change; verify current details with your insurance provider, the manufacturer, or your prescriber before making treatment decisions. Compounded medications are not FDA-approved.
Sources
- Zepbound (tirzepatide) prescribing information, DailyMed (SPL version 40, revised August 2026; Study 4 = SURMOUNT-4, Tables 6 and 7)
- Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024
- Horn DB et al. Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial. JAMA Intern Med. 2026
- Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN). The Lancet. 2026
- Eli Lilly and Company: Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss (SURMOUNT-MAINTAIN results), May 12, 2026
- Jastreboff AM et al. Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1, 3 years). N Engl J Med. 2025
- Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide. Diabetes Obes Metab. 2026
- Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ. 2026
- Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis. EClinicalMedicine. 2025
- Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. 2021
- Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022
- Reduced-Frequency GLP1 Therapy Maintains Weight, Body Composition, and Metabolic Syndrome Improvements: A Case Series. Obesity. 2026
- Sumithran P et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011
- Wing RR et al. A self-regulation program for maintenance of weight loss (STOP Regain). N Engl J Med. 2006
- NIDDK (NIH): Prescription Medications to Treat Overweight and Obesity (last reviewed June 2024; checked November 2026)
- Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society. Obesity. 2025
- LillyDirect: Zepbound self-pay prices and refill terms (checked November 2026)

Tirzepatide Dosage Chart for Weight Loss: Doses, Schedule and Units
October 21, 20268 min

How Long Does Tirzepatide Stay in Your System? Zepbound and Mounjaro
November 15, 20268 min

What Is Microdosing Tirzepatide? What the Evidence Says
November 12, 20267 min

Why Am I Not Losing Weight on Tirzepatide?
November 9, 202610 min
